Related Experiment Videos

New pharmacological strategies in chronic heart failure

R M A van de Wal1, A A Voors, H W M Plokker

  • 1Department of Cardiology, St Antonius Hospital, Heart Lung Center Utrecht, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. r.wal@antonius.net

Cardiovascular Drugs and Therapy
|March 17, 2005
PubMed

Insights

New pharmacological agents for chronic heart failure (CHF) aim to improve outcomes beyond standard treatments. While many new drugs show promise in early studies, clinical results vary, with erythropoietin and eplerenone being the most promising for heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Chronic heart failure (CHF) remains a condition with a poor prognosis despite current cornerstone treatments like diuretics, ACE inhibitors, and beta-blockers.
  • Angiotensin receptor blockers are increasingly used, but novel therapeutic strategies are needed to improve patient outcomes.
  • Numerous new agents targeting diverse neurohormonal pathways and mechanisms have been developed as add-on therapies for CHF.

Purpose of the Study:

  • To provide an overview of emerging pharmacological developments for chronic heart failure.
  • To discuss the clinical value and efficacy of these new agents in managing CHF.
  • To identify promising future therapeutic options for patients with chronic heart failure.

Main Methods:

  • Review of recent clinical trials and preclinical data on novel pharmacological agents for CHF.
  • Analysis of agents targeting various pathways including neurohormonal, immunomodulatory, and growth factor mechanisms.
  • Evaluation of the efficacy and safety profiles of investigational drugs in the context of CHF treatment.

Main Results:

  • Many novel agents, including vasopeptidase inhibitors, endothelin antagonists, and growth hormone therapies, have shown disappointing clinical results.
  • Agents such as caspase inhibitors, adrenomedullin, and vasopressin antagonists are in early stages of development.
  • Erythropoietin and the selective aldosterone receptor antagonist eplerenone currently appear to be the most promising new pharmacological developments for CHF.

Conclusions:

  • Despite extensive research, the clinical translation of many novel CHF therapies has been challenging.
  • Further development and rigorous clinical evaluation are necessary for agents in early development stages.
  • Erythropoietin and eplerenone represent significant advancements and hold considerable promise for improving the management of chronic heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...